Latest news with #Royalties
Yahoo
5 days ago
- Business
- Yahoo
Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ...
Net Loss: $33.5 million or $0.58 per share for Q1 2025, compared to $31.4 million or $0.54 per share in Q4 2024. Cash and Investments: $52.5 million as of March 31, 2025. Debt Reduction: Total debt reduced by $10 million, with near-term repayment obligations lowered from $118 million to $17 million. OMIDRIA Royalties: $6.7 million for Q1 2025 based on net sales of $22.3 million, down from $10.1 million in Q4 2024. Interest Expense: $3.7 million for Q1 2025, reflecting a $477,000 increase from Q4 2024. Operating Expenses: $35 million for Q1 2025, a decrease of $691,000 from Q4 2024. Income from Discontinued Operations: $4.1 million for Q1 2025, down $1.1 million from Q4 2024. Warning! GuruFocus has detected 2 Warning Signs with OMER. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Omeros Corp (NASDAQ:OMER) has successfully negotiated an exchange agreement to extend the maturity of its convertible notes from 2026 to 2029, reducing near-term debt obligations by over $100 million. The company has an active at-the-market facility with the capacity to raise up to $150 million, providing flexibility to access additional capital. The FDA has accepted the resubmitted Biologics License Application for narsoplimab in TA-TMA, with a target action date set for September 25. Omeros Corp (NASDAQ:OMER) is well-prepared for the potential launch of narsoplimab, having identified key transplant centers and engaged with payers to ensure patient access. The company is advancing its pipeline with ongoing clinical trials for zaltenibart in PNH and OMS527 for cocaine use disorder, supported by a grant from the National Institute on Drug Abuse. Negative Points Omeros Corp (NASDAQ:OMER) reported a net loss of $33.5 million for the first quarter of 2025, an increase from the previous quarter. The company has suspended its Expanded Access Program for narsoplimab, affecting patients who lack approved treatment options for TA-TMA. There is a temporary pause on the Phase 3 program for zaltenibart in PNH due to capital considerations, potentially delaying its development timeline. OMIDRIA royalties decreased significantly in the first quarter of 2025 compared to the previous quarter, impacting revenue. Interest expense increased in the first quarter, driven by changes in the OMIDRIA royalty obligation and new convertible notes. Q & A Highlights Q: Can you provide details on the launch plans for narsoplimab and its impact on patient access? A: Greg Demopulos, Chairman & CEO, stated that the company is well-prepared for the launch, expecting it to be successful. Nadia Dac, Chief Commercial Officer, elaborated that the team is focused on the top 40 transplant centers responsible for 60% of the allogeneic transplant volume. They have identified key decision-makers and are engaging with payers, emphasizing narsoplimab's unique value as the only approved treatment for TA-TMA. Q: Can you provide more information about the patients affected by TA-TMA and the associated healthcare costs? A: Greg Demopulos explained that TA-TMA is an unpredictable complication of stem cell transplants, often resulting in rapid deterioration and high mortality. Nadia Dac added that untreated patients incur significant costs, such as ICU stays and organ failure treatments. Narsoplimab aims to reduce these costs by offering an effective outpatient treatment option. Q: How are you managing the financial aspects of the company, particularly regarding debt and capital raising? A: Greg Demopulos highlighted the recent exchange agreement that reduced the 2026 convertible notes' principal, lowering near-term repayment obligations by over $100 million. The company is also exploring partnerships for non-dilutive funding and has an active at-the-market facility to raise up to $150 million. Q: What are the strategic priorities for Omeros beyond narsoplimab? A: Greg Demopulos mentioned that the company is prioritizing the development of zaltenibart for paroxysmal nocturnal hemoglobinuria (PNH) and continuing its PDE7 inhibitor program for cocaine use disorder, funded by a NIDA grant. They are also advancing their oncology platform, Oncotox, targeting acute myeloid leukemia. Q: What is the current status of the narsoplimab BLA resubmission and its potential market impact? A: Greg Demopulos confirmed that the FDA has accepted the resubmitted BLA for narsoplimab in TA-TMA, with a target action date of September 25. The company anticipates narsoplimab to be the first approved therapy for TA-TMA, addressing a nearly $1 billion annual market opportunity. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
06-08-2025
- Business
- Yahoo
Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market's revenue expectations in Q2 CY2025, but sales rose 7.8% year on year to $579 million. Its GAAP profit of $0.16 per share was in line with analysts' consensus estimates. Is now the time to buy Royalty Pharma? Find out in our full research report. Royalty Pharma (RPRX) Q2 CY2025 Highlights: Revenue: $579 million vs analyst estimates of $590 million (7.8% year-on-year growth, 1.9% miss) EPS (GAAP): $0.16 vs analyst estimates of $0.17 (in line) Adjusted EBITDA: $633 million vs analyst estimates of $606.6 million (109% margin, 4.4% beat) Free Cash Flow was $364 million, up from -$138.6 million in the same quarter last year Market Capitalization: $15.97 billion 'We delivered excellent second quarter 2025 results, as the strength of our diversified portfolio drove 20% growth in Portfolio Receipts, and raised our full year guidance,' said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. Company Overview Pioneering a unique business model in the pharmaceutical industry since 1996, Royalty Pharma (NASDAQ:RPRX) acquires rights to receive portions of sales from successful biopharmaceutical products, providing funding to drug developers without conducting research itself. Revenue Growth A company's long-term sales performance can indicate its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Regrettably, Royalty Pharma's sales grew at a tepid 3.6% compounded annual growth rate over the last five years. This wasn't a great result compared to the rest of the healthcare sector, but there are still things to like about Royalty Pharma. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Royalty Pharma's performance shows it grew in the past but relinquished its gains over the last two years, as its revenue fell by 1.2% annually. We can better understand the company's revenue dynamics by analyzing its most important segment, Portfolio Receipts. Over the last two years, Royalty Pharma's Portfolio Receipts revenue averaged 11.8% year-on-year growth. This segment has outperformed its total sales during the same period, lifting the company's performance. This quarter, Royalty Pharma's revenue grew by 7.8% year on year to $579 million, missing Wall Street's estimates. Looking ahead, sell-side analysts expect revenue to grow 26.4% over the next 12 months, an improvement versus the last two years. This projection is eye-popping and implies its newer products and services will catalyze better top-line performance. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Operating Margin Operating margin is a key measure of profitability. Think of it as net income - the bottom line - excluding the impact of taxes and interest on debt, which are less connected to business fundamentals. Royalty Pharma has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average operating margin of 54.3%. Looking at the trend in its profitability, Royalty Pharma's operating margin rose by 31.9 percentage points over the last five years, as its sales growth gave it operating leverage. This performance was mostly driven by its recent improvements as the company's margin has increased by 84.1 percentage points on a two-year basis. in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Sadly for Royalty Pharma, its EPS declined by 17.3% annually over the last five years while its revenue grew by 3.6%. However, its operating margin actually improved during this time, telling us that non-fundamental factors such as interest expenses and taxes affected its ultimate earnings. Diving into the nuances of Royalty Pharma's earnings can give us a better understanding of its performance. A five-year view shows Royalty Pharma has diluted its shareholders, growing its share count by 58.8%. This dilution overshadowed its increased operating efficiency and has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals. In Q2, Royalty Pharma reported EPS at $0.16, in line with the same quarter last year. This print missed analysts' estimates. We also like to analyze expected EPS growth based on Wall Street analysts' consensus projections, but there is insufficient data. Key Takeaways from Royalty Pharma's Q2 Results We struggled to find many positives in these results. Its EPS missed and its revenue fell short of Wall Street's estimates. Overall, this was a weaker quarter. The stock traded down 1.7% to $37.25 immediately after reporting. Royalty Pharma underperformed this quarter, but does that create an opportunity to invest right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
The Sun
29-04-2025
- Entertainment
- The Sun
Clueless star Twink Caplan resurfaces with her quirky charm for the first time in 5 years as 90s movie gets reboot
CLUELESS star Twink Caplan, who played the bubbly Miss Toby Geist in the hit 90s film, has resurfaced for the first time in five years. The actress, now 77, was spotted running errands near her Los Angeles home on April 25. 10 10 10 10 10 Dressed in cargo pants and a flannel shirt featuring photos of a donkey, Twink carried a stuffed crocodile and a robot shark as she stepped out of grocery chain Erewhon. Three decades after the hit film, she still sported her signature red hair. Twink last acted in an uncredited role for the 2020 Quibi show Royalties starring Darren Criss and directed by Clueless showrunner Amy Heckerling. In her last interview that same year, Twink reflected on her iconic role as the quirky teacher set up by Cher (Alicia Silverstone) and Dionne (Stacey Dash). 'It moves me to think that I would move anybody or that they would like me that much,' she told Today in July 2020. She also loved Miss Geist's romance with Mr. Hall, played by Wallace Shawn. 'When they found each other, it completed them. And it was genuinely kind of pulling your heartstrings," she gushed. 'Oh, what a great time in life," she said of the film's popularity in the 90s. "It was so pure and happy. And the jokes were amazing. "But it was a time where all the characters loved each other. They were real friends. And they were rooting for each other. "That's what's so wonderful about Clueless: it was happy. And I think you get happy when you watch it because there's no enemy. There's no bad guy.' CLUELESS IS BACK Last week, news broke that actress Alicia, 48, is bringing back Clueless as a Peacock sequel series. She will also serve as an executive producer, along with original film director Amy Heckerling. It is unclear if Twink will reprise her role for the reboot. She did, however, play Miss Geist again on the Clueless TV series, which ran from 1996 to 1999 on ABC and then UPN. The original Clueless took the world by storm when it hit theaters in 1995, catapulting Alicia and the other teen stars including the late Brittany Murphy to fame. The movie even has caught the attention of a much younger generation, as Kim Kardashian and daughter North, 11, dressed up as Cher and Dionne for Halloween in 2023. 10 10 10 10 10
